Co-administer antihistamine or systemic steroid over the short term in cases where nasal symptoms worsen during treatment w/ fluticasone furoate, & gradually reduce dose of co-administered drug when symptoms improve. Reduce dose when symptomatic improvement is maintained in cases of long-term use in patients w/ perennial allergic rhinitis. Risk of systemic effects (including Cushing's syndrome, cushingoid features, adrenocortical suppression, growth retardation in childn, decreased bone density, cataract, glaucoma, & central serous chorioretinopathy), particularly in the event of long-term or high-dose administration. Caution in patients w/ nose & throat infections (excluding infections for which no effective antibacterial drugs exist, or deep mycoses); w/ recurrent epistaxis; w/ severe hypertrophic rhinitis or nasal polyps; on long-term or high-dose systemic steroid therapy. Effect against nasal congestion may be masked in patients who are taking antihypertensives (eg, reserpine & α-methyldopa). Administer in pregnant women & women who may be pregnant only when therapeutic benefits outweigh risks. Consider whether to continue or discontinue breastfeeding w/ benefits of treatment & benefits of breastfeeding in mind. No clinical studies have been conducted in low-birth-wt babies, newborns, babies, or infants <2 yr. Carefully administer in the elderly.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
